7 citations
,
October 2008 in “Arthritis Care & Research” Aggressive immunosuppressive treatment improved a woman's severe heart condition linked to autoimmune disease.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” miR-486 may help prevent hair loss in alopecia areata.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
August 2023 in “Dermatology and Therapy” Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.
1 citations
,
May 2025 in “Clinical Reviews in Allergy & Immunology”
Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.
3 citations
,
October 2024 in “Cancers” Skin side effects from melanoma immunotherapy are common and may indicate better survival.
2 citations
,
January 2020 in “Enlighten: Theses (The University of Glasgow)” Alopecia areata is an autoimmune disease causing hair loss, and targeting macrophages may help treat it.
3 citations
,
January 2023 in “JEADV Clinical Practice” IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
26 citations
,
February 2021 in “FEBS Journal” Targeting regulatory T cells may help treat age-related diseases.
February 2023 in “Reactions Weekly” 2 citations
,
January 2026 in “Frontiers in Endocrinology” Next-generation Treg therapies could help achieve lasting immune tolerance in type 1 diabetes.
February 2011 in “Journal of Investigative Dermatology” New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
41 citations
,
February 2001 in “Current pharmaceutical design” Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
3 citations
,
April 2011 in “Klinische Pädiatrie” Immunosuppression therapy with methylprednisolone effectively treats childhood alopecia areata.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
Topical corticosteroids are effective for skin conditions but can have side effects.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
48 citations
,
January 2024 in “Immune Network” IL-15 is key for T cell function and could help improve treatments for immune-related diseases.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Biological therapy boosts the immune system to effectively fight melanoma.
101 citations
,
July 1998 in “Journal of Investigative Dermatology” UVB exposure in human skin causes macrophages to produce more IL-10 and less IL-12, leading to immunosuppression.
1 citations
,
July 2015 in “British Journal of Dermatology” Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.
October 1984 in “Immunology Today” June 2026 in “Frontiers in Immunology” JAK inhibitors effectively treat inflammatory skin diseases by targeting specific cytokine signals.